News

Article

Viridian Therapeutics announces positive long-term durability data for veligrotug for the treatment of active thyroid eye disease

Key Takeaways

  • Veligrotug showed sustained proptosis response in 70% of patients at 52 weeks, maintaining a favorable safety profile.
  • The THRIVE phase 3 trial met all primary and secondary end points, reinforcing veligrotug's potential as a leading TED treatment.
SHOW MORE

Viridian Therapeutics reveals promising long-term results for veligrotug in treating thyroid eye disease, highlighting its potential as a leading therapy.

(Image Credit: AdobeStock/khunkornStudio)

(Image Credit: AdobeStock/khunkornStudio)

Viridian Therapeutics has announced positive long-term durability data from THRIVE, its phase 3 clinical trial of veligrotug for the treatment of active thyroid eye disease (TED).

Veligrotug is an intravenously delivered anti–IGF-1R antibody. The company also notes that veligrotug has the potential to “improve patient experience with a differentiated dosing regimen featuring a shorter infusion time and fewer infusions compared [with] the currently approved and marketed IGF-1R inhibitor.”

The THRIVE trial evaluated 5 infusions of veligrotug or placebo every 3 weeks, with a primary topline analysis at week 15, and followed patients through week 52.

At 52 weeks, 70% of patients taking veligrotug (21/30) who were proptosis responders at week 15 and continued follow-up to the end of the study maintained their proptosis response. The company defined maintenance of response as responders at week 15 who still had at least a 2-mm reduction in proptosis compared with baseline at week 52, without worsening in the fellow eye (≥2-mm increase).

Additionally, no changes to the safety profile in the follow-up period were seen, with the vast majority of adverse events reported at the week 15 primary analysis resolved by week 52.

Steve Mahoney, Viridian’s president and CEO, commented on the data in a press release from the company.1

“We view the strength of today’s durability and safety resolution data as reinforcing veli’s strong and consistently robust clinical profile,” said Mahoney. “We believe that the totality of veligrotug’s clinical data continues to demonstrate its potential to be the treatment of choice for patients living with TED. We believe these data, together with a streamlined dosing regimen of 5 infusions, position veli to become a market-leading TED therapeutic, if approved.”

As previously reported,2 the THRIVE trial met the primary and all secondary end points at 15 weeks after 5 infusions of veligrotug. Additionally, the THRIVE-2 trial3 met all primary and secondary end points at the 15-week primary analysis time point after 5 infusions of veligrotug.

Recently,4 veligrotug received a breakthrough therapy designation from the FDA. Breakthrough therapy designation is reserved for drug candidates intended to treat serious or life-threatening conditions that address an unmet need where clinical evidence has indicated they may demonstrate substantial improvement on a clinically significant end point over existing therapies.

The company noted that it intends to submit a biologics license application (BLA) for veligrotug for the treatment of TED in the second half of 2025, with a potential launch in 2026 pending approval.

Looking forward, the company is currently dosing patients in 2 global phase 3 clinical trials for VRDN-003, REVEAL-1 and REVEAL-2, in active and chronic TED, respectively. The company expects topline data from the trials in the first half of 2026 and plans to submit a BLA for VRDN-003 by the end of 2026.

References
  1. Viridian Therapeutics announces positive long-term durability data from the veligrotug phase 3 THRIVE clinical trial in patients with active thyroid eye disease (TED). News release. Viridian Therapeutics, Inc. May 20, 2025. Accessed May 20, 2025. https://investors.viridiantherapeutics.com/news/news-details/2025/Viridian-Therapeutics-Announces-Positive-Long-Term-Durability-Data-from-the-Veligrotug-Phase-3-THRIVE-Clinical-Trial-in-Patients-with-Active-Thyroid-Eye-Disease-TED/default.aspx
  2. Harp MD. Viridian announces positive topline data from phase 3 THRIVE trial evaluating veligrotug in patients with active TED. Ophthalmology Times. September 12, 2024. Accessed May 20, 2025. https://www.ophthalmologytimes.com/view/viridian-announces-positive-topline-data-from-phase-3-thrive-trial-evaluating-veligrotug-in-patients-with-active-ted
  3. Harp MD. Viridian announces topline data from THRIVE-2 phase 3 clinical trial of veligrotug for treatment of thyroid eye disease. Ophthalmology Times. December 18, 2024. Accessed May 20, 2025. https://www.ophthalmologytimes.com/view/viridian-announces-topline-data-from-thrive-2-phase-3-clinical-trial-of-veligrotug-for-treatment-of-thyroid-eye-disease
  4. Viridian Therapeutics receives FDA breakthrough therapy designation for veligrotug for the treatment of thyroid eye disease (TED). News release. Viridian Therapeutics, Inc. May 7, 2025. Accessed May 20, 2025. https://investors.viridiantherapeutics.com/news/news-details/2025/Viridian-Therapeutics-Receives-FDA-Breakthrough-Therapy-Designation-for-Veligrotug-for-the-Treatment-of-Thyroid-Eye-Disease-TED/default.aspx

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
© 2025 MJH Life Sciences

All rights reserved.